Using terlipressin to prevent kidney injury after liver transplantation
Effect of Intraoperative Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients: a Randomized, Double-blind, Placebo-controlled Study
This study is testing if giving terlipressin to people getting a liver transplant can help prevent kidney injury after the surgery.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 104 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Beijing Tsinghua Chang Gung Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06108362 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effect of terlipressin, a vasopressin receptor agonist, on reducing the incidence of early postoperative acute kidney injury in patients undergoing liver transplantation. Participants are randomly assigned to receive either terlipressin or a placebo during the perioperative period. The study aims to improve kidney perfusion and blood pressure, potentially mitigating one of the common complications associated with liver transplants. By comparing outcomes between the two groups, researchers hope to determine the efficacy of terlipressin in this context.
Who should consider this trial
Good fit: Ideal candidates are patients scheduled for liver transplantation who can provide informed consent.
Not a fit: Patients under 18 years old or those with severe pre-existing health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of acute kidney injury in liver transplant patients, leading to better postoperative outcomes.
How similar studies have performed: While the use of terlipressin in this specific context is novel, similar studies have shown promise in improving kidney outcomes in other surgical settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1) Patients who plan to undergo liver transplantation in our hospital 2) Patients or family members sign informed consent Exclusion Criteria: * Patients \<18 years old;② Patients undergoing autologous liver transplantation or combined transplantation;③ Patients with lower extremity artery stenosis;(4) Patients with severe heart disease、lung disease、kidney disease;⑤ Patients with severe lung disease;⑥ Patients who used renal replacement therapy before surgery;⑦ the depth of one kidney from the body surface is greater than 4cm;⑧ Patients treated with terlipressin within 2 weeks before surgery⑨ Patients allergic to terlipressin.
Where this trial is running
Beijing, Beijing
- Beijing Tsinghua Chang Gung Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Ziheng Qi, Doctor
- Email: 469836626@qq.com
- Phone: 15373598688
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.